Our Business Partner
Actoverco
By employing more than 2000 country’s efficient young people in 15 medical fields with more than 320 pharmaceutical products possessing the highest standards approved by domestic and international organizations, Actover group has been able to develop the greatest and the most experienced private pharmaceutical group in Iran and the Middle East.
Actover group has been established with the aim of production and supply of the pharmaceutical needs of Iranian patients and achieving the best quality, at the global level, also has always been one of the leading companies in manufacturing the best drugs in the Iranian market and the region.
Actoverco Pharmaceutical Factories 1 and 2
Manufacturer of more than six billion tablets and capsules each year
In 2011, Actoverco 1 factory was established as the first factory of the Actoverco group. Actoverco 2 factory, as one of the most advanced and high throughput production lines of tablets and capsules in the country, was initiated in 2018 in order to increase the production capacity and meet the demand of patients. Intelligent air and pressure control system, GMP-oriented classification, and the production capacity of thousands of kilograms of granules per day are among the unique features of the Actover 1 and 2 factories.
![actoverco-Image-02 actoverco-Image-02](https://acteropharma.com/wp-content/uploads/elementor/thumbs/actoverco-Image-02-pwok4epcusymixxuyzapz2yow0h3xkaduktgdlswog.jpg)
![Actoverco -02 Actoverco -02](https://acteropharma.com/wp-content/uploads/elementor/thumbs/Actoverco-02-pxycpzdf8y1yq1df55rx2f9j4hz8dhzezp2n1nlisw.png)
Actoverco Biotech factory
Dedicated site for the production of recombinant drugs and monoclonal antibodies
The biotechnology site, with more than 3,000 m2 of total infrastructure, including 2,000 m2 of clean rooms and a production capacity of more than 40 million vials and pre-filled syringes, was launched in 2014 with the aim of producing recombinant drugs such as MS drugs and monoclonal antibodies.
At the beginning of 2018, Phase 2 of biotechnology factory started its activities with an infrastructure of about 5000 m2, including 3000 m2 of clean rooms. In this project, single-use bioreactor technology has been used for the first time in Iran and the Middle East.
![](https://acteropharma.com/wp-content/uploads/2022/10/Actover2.jpg)